Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

13.8%

4 terminated/withdrawn out of 29 trials

Success Rate

85.2%

-1.3% vs industry average

Late-Stage Pipeline

41%

12 trials in Phase 3/4

Results Transparency

39%

9 of 23 completed trials have results

Key Signals

1 recruiting9 with results

Enrollment Performance

Analytics

Phase 1
15(53.6%)
Phase 3
11(39.3%)
Phase 2
1(3.6%)
Phase 4
1(3.6%)
28Total
Phase 1(15)
Phase 3(11)
Phase 2(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials
NCT06460064Phase 1Completed

First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LP

Role: lead

NCT05366868Phase 4Active Not Recruiting

Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus

Role: collaborator

NCT05359081Phase 3Terminated

A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan

Role: lead

NCT06482268Phase 1Recruiting

Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)

Role: collaborator

NCT04825860Phase 2Terminated

A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Role: lead

NCT05435729Phase 1Completed

A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease

Role: lead

NCT00711269Phase 3Completed

Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Role: lead

NCT00286169Phase 3Terminated

Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

Role: lead

NCT03563560Phase 1Completed

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

Role: lead

NCT02641873Phase 1Completed

A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer

Role: lead

NCT01614912Phase 3Completed

Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Role: lead

NCT04325737Phase 1Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia

Role: lead

NCT02750891Phase 1Completed

A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas

Role: lead

NCT02358395Phase 1Completed

A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma

Role: lead

NCT01986114Phase 3Completed

A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.

Role: lead

NCT02436252Phase 1Completed

Study of DSP-7888 in Patients With Myelodysplastic Syndrome

Role: lead

NCT00925678Phase 1Completed

DSP-3025 Study of Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season

Role: lead

NCT01207011Phase 3Completed

Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer

Role: lead

NCT02335658Phase 3Completed

Long-term Study of DSP-5423P in Patients With Schizophrenia

Role: lead

NCT02354898Phase 1Completed

A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma

Role: lead